3-Substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: Mechanism of activation and cytotoxicity in vitro

Biochemical Pharmacology

Volumn 66, Issue 7, 2003, Pages 1199-1206

  Jaffar, Mohammed ^a   Phillips, Roger M ^b   Williams, Kaye J ^a   Mrema, Ibrahim ^a   Cole, Christian ^a   Wind, Natasha S ^a   Ward, Timothy H ^c   Stratford, Ian J ^a   Patterson, Adam V ^a,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bioreduction; Enzyme directed; Hypoxic cytotoxin; Indolequinone; Mitomycin C (MMC); NQO1

Indexed keywords

1 FORMYL 5 [2 (METHYL)LAZIRIDIN 1 YL] 1 METHYLINDOLE 4,7 DIONE; 5 (1 METHYLAZIRIDINYL) 3 FORMYL 1 METHYLINDOLE 4,7 DIONE; 5 AZIRIDINYL 1 FORMYL 1 METHYLINDOLE 4,7 DIONE; 5 AZIRIDINYL 3 HYDROXYMETHYL 1 METHYLINDOLE 4,7 DIONE; ALDEHYDE DERIVATIVE; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; METHYL GROUP; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL CLONING; CELL HYPOXIA; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

EID: 0141628918     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00452-0     Document Type: Article

References (36)

1. Kumar G.S., Lipman R., Cummings J., Tomasz M. Mitomycin C-DNA adducts generated by DT-diaphorase. Revised mechanism of the enzymatic reductive activation of mitomycin C. Biochemistry. 36:1997;14128-14136.
2. Warren A.J., Maccubbin A.E., Hamilton J.W. Detection of mitomycin C-DNA adducts in vivo by P-32-postlabeling: time coarse for formation and removal of adducts and biochemical modulation. Cancer Res. 58:1998;453-461.
3. Palom Y., Belcourt M.F., Tang L.Q., Mehta S.S., Sartorelli A.C., Pritsos C.A., Pritsos K.L., Rockwell S., Tomasz M. Bioreductive metabolism of mitomycin C in EMT6 mouse mammary tumor cells: cytotoxic and non-cytotoxic pathways, leading to different types of DNA adducts. The effect of dicumarol. Biochem. Pharmacol. 61:2001;1517-1529.
4. Naylor M.A., Jaffar M., Nolan J., Stephens M.A., Butler S., Patel K.B., Everett S.A., Adams G.E., Stratford I.J. 2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo. J. Med. Chem. 40:1997;2335-2346.
5. Jaffar M., Naylor M.A., Robertson N., Lockyer S.D., Phillips R.M., Everett S.A., Adams G.E., Stratford I.J. 5-Substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en-1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro. Anti-Cancer Drug Des. 13:1998;105-123.
6. Beall H.D., Winski S., Swann E., Hudnott A.R., Cotterill A.S., O'Sullivan N., Green S.J., Bien R., Siegel D., Ross D., Moody C.J. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity. Med. Chem. 41:1998;4755-4766.
7. Moody C.J., Roffey J.R.A., Swann E., Lockyer S., Houlbrook S., Stratford I.J. Synthesis and cytotoxic activity of thiazolyl indolequinones. Anti-Cancer Drugs. 10:1999;577-589.
8. Swann E., Barraja P., Oberlander A.M., Gardipee W.T., Hudnott A.R., Beall H.D., Moody C.J. Indolequinone antitumor agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Part 2. J. Med. Chem. 44:2001;3311-3319.
9. Skibo E.B., Xing C.G., Dorr R.T. Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity. J. Med. Chem. 44:2001;3545-3562.
10. Winski S.L., Swann E., Hargreaves R.H.J., Dehn D.L., Butler J., Moody C.J., Ross D. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinines. Biochem. Pharmacol. 61:2001;1509-1516.
11. Ross D., Kepa J.K., Winski S.L., Beall H.D., Anwar A., Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact. 129:2000;77-97.
12. Chen S., Wu K.B., Knox R. Structure-function studies of DT-diaphorase (NQO1) and NRH: quinone oxidoreductase (NQO2). Free Radic. Biol. Med. 29:2000;276-284.
13. Stratford I.J., Workman P. Bioreductive drugs into the next millennium. Anti-Cancer Drug. Des. 13:1998;519-528.
14. Saunders M.P., Jaffar M., Patterson A.V., Nolan J., Naylor M.A., Phillips R.M., Harris A.L., Stratford I.J. The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. Biochem. Pharmacol. 59:2000;993-996.
15. Jaffar M., Naylor M.A., Robertson N., Stratford I.J. Targeting hypoxia with a new generation of indolequinones. Anti-Cancer Drug Des. 13:1998;593-609.
16. Naylor M.A., Swann E., Everett S.A., Jaffar M., Nolan J., Robertson N., Lockyer S.D., Patel K.B., Dennis M.F., Stratford M.R.L., Wardman P., Adams G.E., Moody C.J., Stratford I.J. Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro. J. Med. Chem. 41:1998;2720-2731.
17. Jaffar M., Everett S.A., Naylor M.A., Moore S.G., Ulhaq S., Patel K.B., Stratford M.R.L., Nolan J., Wardman P., Stratford I.J. Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones. Bioorg. Med. Chem. Lett. 9:1999;113-118.
18. Moody C.J., Norton C.L., Slawin A.M.Z., Taylor S. Cyclopropyl indolequinones: mechanistic probes for bioreductive anticancer drug action. Anti-Cancer Drug Des. 13:1998;611-634.
19. Phillips R.M., Naylor M.A., Jaffar M., Doughty S.W., Everett S.A., Breen A.G., Choudry G.A., Stratford I.J. Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships. J. Med. Chem. 42:1999;4071-4080.
20. Phillips R.M. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase. Biochem. Pharmacol. 52:1996;1711-1718.
21. Chen H.H., Ma J.X., Forrest G.L., Deng P.S.K., Martino P.A., Lee T.D., Chen S. Expression of rat-liver NAD(P)H-quinone-acceptor oxidoreductase in Escherichia coli and mutagenesis in vitro at Arg-177. Biochem. J. 284:1992;855-860.
22. Hobbs S., Jitrapakdee S., Wallace J.C. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1 alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem. Biophys. Res. Commun. 252:1998;368-372.
23. Sharp S.Y., Kelland L.R., Valenti M.R., Brunton L.A., Hobbs S., Workman P. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol. Pharmacol. 58:2000;1146-1155.
24. Robertson N., Haigh A., Adams G.E., Stratford I.J. Factors affecting sensitivity to EO9 in rodent and human tumor-cells in-vitro - DT diaphorase activity and hypoxia. Eur. J. Cancer. 30A:1994;1013-1019.
25. Patterson A.V., Barham H.M., Chinje E.C., Adams G.E., Harris A.L., Stratford I.J. Importance of p450 reductase-activity in determining sensitivity of breast-tumor cells to the bioreductive drug, tirapazamine (SR-4233). Br. J. Cancer. 72:1995;1144-1150.
26. Stratford I.J., Stephens M.A. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int. J. Radiat. Oncol. Biol. Phys. 16:1989;973-976.
27. Ward T.H., Butler J., Shahbakhti H., Richards J.T. Comet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells. Biochem. Pharmacol. 53:1997;1115-1121.
28. Beall H.D., Hudnott A.R., Winski S., Siegel D., Swann E., Ross D., Moody C.J. Indolequinone antitumor agents: relationship between quinone structure and rate of metabolism by recombinant human NQO1. Bioorg. Med. Chem. Lett. 8:1998;545-548.
29. Cadenas E. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem. Pharmacol. 49:1995;127-140.
30. Faig M., Bianchet M.A., Talalay P., Chen S., Winski S., Ross D., Amzel L.M. Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. Proc. Natl. Acad. Sci. U.S.A. 97:2000;3177-3182.
31. Faig M., Bianchet M.A., Winski S., Hargreaves R., Moody C.J., Hudnott A.R., Ross D., Amzel L.M. Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinines. Structure. 9:2001;659-667.
32. Marshall R.S., Rauth A.M. Modification of the cytotoxic activity of mitomycin-C by oxygen and ascorbic acid in Chinese-hamster ovary cells and a repair-deficient mutant. Cancer Res. 46:1986;2709-2713.
33. Plumb J.A., Workman P. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin-c in a human colon-tumor cell-line that lacks DT-diaphorase activity. Int. J. Cancer. 56:1994;134-139.
34. Belcourt M.F., Hodnick W.F., Rockwell S., Sartorelli A.C. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. Proc. Natl. Acad. Sci. U.S.A. 93:1996;456-460.
35. Hernick M., Flader C., Borch R.F. Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase. J. Med. Chem. 45:2002;3540-3548.
36. Flader C., Liu J.W., Borch R.F. Development of novel quinone phosphorodiamidate prodrugs targeted to DT-diaphorase. J. Med. Chem. 43:2000;3157-3167.